A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

NCT05910827 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
398
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Hummingbird Bioscience

Collaborators